Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $417.50, for a total transaction of $9,393,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total transaction of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $421.80, for a total transaction of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $416.35, for a total transaction of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total transaction of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The stock was sold at an average price of $397.41, for a total transaction of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00.

United Therapeutics Trading Up 9.6%

United Therapeutics stock opened at $455.32 on Thursday. The stock has a market cap of $20.54 billion, a P/E ratio of 17.77, a price-to-earnings-growth ratio of 4.53 and a beta of 0.66. The company has a fifty day simple moving average of $404.55 and a 200-day simple moving average of $336.05. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $479.50.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the company earned $6.39 EPS. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on UTHR. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Wednesday. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Finally, Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $462.54.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of UTHR. Chung Wu Investment Group LLC acquired a new position in United Therapeutics in the second quarter valued at $29,000. WealthCollab LLC increased its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. SVB Wealth LLC acquired a new position in United Therapeutics in the first quarter valued at $32,000. Finally, Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.